Guobang Pharma (SH:605507)2022-10-18 16:00Financial Performance - The company's operating revenue for Q3 2022 was ¥1,409,879,885.52, representing a year-on-year increase of 45.23%[5] - The net profit attributable to shareholders for Q3 2022 was ¥226,026,296.21, reflecting a year-on-year growth of 57.63%[5] - The basic earnings per share for Q3 2022 was ¥0.40, an increase of 48.15% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥219,365,922.00, up 63.04% year-on-year[5] - Total operating revenue for the first three quarters of 2022 reached ¥4,113,348,595.70, a significant increase of 28.0% compared to ¥3,213,201,476.59 in the same period of 2021[25] - Net profit for the first three quarters of 2022 was ¥721,356,274.77, representing a 38.3% increase from ¥521,648,888.67 in the same period of 2021[32] - Earnings per share for the first three quarters of 2022 were ¥1.29, compared to ¥1.06 in the same period of 2021[34] Assets and Liabilities - The total assets at the end of the reporting period were ¥8,760,094,524.84, showing a year-on-year increase of 16.60%[7] - As of September 30, 2022, the company's total assets reached ¥8,760,094,524.84, an increase from ¥7,513,072,302.93 at the end of 2021, representing a growth of approximately 16.6%[19] - The total liabilities increased to ¥5,200,000,000, reflecting a growth of approximately 15% compared to the previous year[22] - The total liabilities increased to ¥1,804,755,245.25 in 2022 from ¥1,167,378,598.11 in 2021, reflecting a growth of 54.4%[23] - The total equity attributable to shareholders at the end of the reporting period was ¥6,955,416,928.10, an increase of 9.60% year-on-year[7] - The total equity attributable to shareholders reached ¥6,955,416,928.10, an increase from ¥6,346,079,448.81 in the previous year, marking a growth of 9.6%[23] Cash Flow - The company reported a net cash flow from operating activities of ¥611,755,154.41 for the year-to-date period[5] - The net cash flow from operating activities for the first three quarters of 2022 was RMB 611,755,154.41, a significant improvement compared to a negative cash flow of RMB -50,481,356.46 in the same period of 2021[36] - Total cash inflow from investment activities in the first three quarters of 2022 was RMB 3,192,741,655.56, compared to RMB 1,196,583,611.02 in 2021, indicating a substantial increase[40] - The net cash flow from financing activities for the first three quarters of 2022 was RMB 472,113,835.59, down from RMB 1,930,678,325.30 in the previous year[40] - The total cash and cash equivalents at the end of the third quarter of 2022 reached RMB 1,620,785,580.47, an increase from RMB 1,288,226,413.62 at the end of the same period in 2021[40] Operational Highlights - The company experienced a significant increase in product sales volume due to the launch of new products, contributing to revenue growth[9] - The company has plans for market expansion and new product development, although specific figures were not disclosed during the call[20] - The company emphasized the importance of strategic partnerships and potential acquisitions to enhance market presence and operational efficiency[20] Costs and Expenses - Total operating costs for the first three quarters of 2022 were ¥3,284,254,518.76, up 26.0% from ¥2,605,167,043.75 in the previous year[28] - Research and development expenses for the first three quarters of 2022 amounted to ¥135,060,342.49, up from ¥106,211,901.82 in the same period of 2021, indicating a 27.2% increase[28] - The company reported a financial expense of -¥67,552,195.26, a significant improvement compared to a financial expense of ¥20,810,750.92 in the previous year[28] Inventory and Receivables - Accounts receivable increased to ¥607,729,077.71 from ¥445,030,444.75, reflecting a rise of approximately 36.5%[19] - Inventory levels rose to ¥1,417,964,236.59, compared to ¥1,309,329,113.87, marking an increase of around 8.3%[19] Non-Recurring Items - Non-recurring gains for Q3 2022 amounted to ¥6,660,374.21, with minimal impact on overall profitability[8]